GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT00930163
Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy
Phase 1
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT00928330
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
Phase 1
Completed
- Conditions
- Solid Cancers
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT00927589
A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00909740
A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1097
- Registration Number
- NCT00891735
A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT00888745
- Locations
- 🇭🇺
Investigational Site, Szeged, Hungary
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00876122
A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT00876109
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Phase 1
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT00873756
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
Phase 2
Completed
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT00866788
© Copyright 2025. All Rights Reserved by MedPath